Using HJC0152 to target glucose metabolism in metastatic breast cancer
Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer
['FUNDING_R01'] · LSU HEALTH SCIENCES CENTER · NIH-10703216
This study is looking at a new treatment called HJC0152 for people with metastatic breast cancer, especially those with the aggressive triple-negative type, to see if it can slow down cancer growth by changing how cancer cells use sugar for energy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | LSU HEALTH SCIENCES CENTER (nih funded) |
| Locations | 1 site (NEW ORLEANS, UNITED STATES) |
| Trial ID | NIH-10703216 on ClinicalTrials.gov |
What this research studies
This research investigates the potential of HJC0152 as a treatment for metastatic breast cancer (MBC) by targeting the abnormal glucose metabolism that many cancer cells rely on for growth. The study focuses on understanding how disrupting glucose metabolism can inhibit the progression of various breast cancer subtypes, particularly triple-negative breast cancer, which is known for its aggressive nature. By exploring this novel approach, the research aims to develop effective therapies for patients who do not respond to existing treatments. Patients may be monitored for changes in tumor behavior and response to the treatment over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic breast cancer, especially those with triple-negative or non-responsive ER-positive subtypes.
Not a fit: Patients with localized breast cancer or those who have not been diagnosed with metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new targeted therapy for patients with metastatic breast cancer, particularly those who have limited treatment options.
How similar studies have performed: Other research has shown promise in targeting glucose metabolism in cancer treatment, indicating that this approach may lead to significant advancements in therapy.
Where this research is happening
NEW ORLEANS, UNITED STATES
- LSU HEALTH SCIENCES CENTER — NEW ORLEANS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHEN, QIANG — LSU HEALTH SCIENCES CENTER
- Study coordinator: SHEN, QIANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancers